share_log

Allarity Therapeutics | DEFA14A: Others

Allarity Therapeutics | DEFA14A: Others

Allarity Therapeutics | DEFA14A：其他
美股SEC公告 ·  07/26 06:09

Moomoo AI 已提取核心信息

Allarity Therapeutics, Inc. has announced the postponement of its 2024 Annual Meeting of Stockholders, which was originally scheduled for July 26, 2024. The decision to delay the meeting was made by the company's board of directors on July 25, 2024, one day before the planned event. The board cited the company's bylaws as the basis for their authority to reschedule the meeting. A new date for the Annual Meeting has yet to be determined, but the board will establish this date and, if necessary, a new record date for stockholder voting eligibility. The company will issue a notice and, if applicable, an updated Proxy Statement to all eligible stockholders based on the original record date of June 14, 2024, or a new record date. This information was provided in a supplement to the Proxy Statement filed with the Securities and Exchange Commission on July 1, 2024. Allarity Therapeutics has urged stockholders to review the Proxy Statement and other relevant documents filed with the SEC for more information regarding the Annual Meeting and the matters to be voted on.
Allarity Therapeutics, Inc. has announced the postponement of its 2024 Annual Meeting of Stockholders, which was originally scheduled for July 26, 2024. The decision to delay the meeting was made by the company's board of directors on July 25, 2024, one day before the planned event. The board cited the company's bylaws as the basis for their authority to reschedule the meeting. A new date for the Annual Meeting has yet to be determined, but the board will establish this date and, if necessary, a new record date for stockholder voting eligibility. The company will issue a notice and, if applicable, an updated Proxy Statement to all eligible stockholders based on the original record date of June 14, 2024, or a new record date. This information was provided in a supplement to the Proxy Statement filed with the Securities and Exchange Commission on July 1, 2024. Allarity Therapeutics has urged stockholders to review the Proxy Statement and other relevant documents filed with the SEC for more information regarding the Annual Meeting and the matters to be voted on.
Allarity Therapeutics, Inc.宣布推迟其原定于2024年7月26日举行的2024年股东年会。董事会于2024年7月25日，在计划的活动前一天做出了推迟会议的决定。董事会以公司章程为基础，行使重新安排会议的权力。股东年会的新日期尚未确定，但董事会将确定这个日期，如果需要，还将确定新的股东投票资格登记日。公司将根据原始登记日期2024年6月14日或新的登记日期向所有符合资格的股东发出通知，并在必要时发布更新的代理声明。此信息是在2024年7月1日提交给证券交易委员会的代理声明补充中提供的。Allarity Therapeutics敦促股东审查代理声明和提交给SEC的其他相关文件，以获取关于年度股东大会和待投票事项的更多信息。
Allarity Therapeutics, Inc.宣布推迟其原定于2024年7月26日举行的2024年股东年会。董事会于2024年7月25日，在计划的活动前一天做出了推迟会议的决定。董事会以公司章程为基础，行使重新安排会议的权力。股东年会的新日期尚未确定，但董事会将确定这个日期，如果需要，还将确定新的股东投票资格登记日。公司将根据原始登记日期2024年6月14日或新的登记日期向所有符合资格的股东发出通知，并在必要时发布更新的代理声明。此信息是在2024年7月1日提交给证券交易委员会的代理声明补充中提供的。Allarity Therapeutics敦促股东审查代理声明和提交给SEC的其他相关文件，以获取关于年度股东大会和待投票事项的更多信息。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间